A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis
← catalyst calendarSponsored by Incyte Corporation (industry) · INCY — their whole pipeline →.
Phase
Phase 3
Status
Completed
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
241actual
Sites
94
Countries
Australia, Belgium, Bulgaria +11
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-04-26 | actual | When the study began enrolling |
| Primary completion | 2025-05-21 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-10-17 | actual | The whole study's end, after follow-up |
| First posted | 2024-02-02 | actual | When this record first appeared on the registry |
| Results posted | 2026-05-22 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-05-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Atopic Dermatitis
Interventions
- Drug: Ruxolitinib Cream — also filed as INCB018424 Phosphate Cream
- Drug: Vehicle Cream
Primary outcomes
what the primary-completion date above is the date OFPercentage of Participants Achieving a ≥75% Improvement in the Eczema Area and Severity Index Score (EASI75) at Week 8
measured Baseline; Week 8
Percentage of Participants With Investigator's Global Assessment Treatment Success (IGA-TS) at Week 8
measured Baseline; Week 8
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2024-08-08 · 1.0 MB · Prot_000.pdf
Statistical Analysis Planposted 2025-05-06 · 659 KB · SAP_001.pdf
Permalink · INCY's whole pipeline · Catalyst calendar · Every registered study · What changed